Shuwen Biotech of Deqing will partner with Bliss Biopharma, a one-year-old Hangzhoucompany, to develop companion diagnostics for BlissBio’s oncology drug candidates. Shuwen will also provide testing services in its CAP-certified central labs for BlissBio clinical trials. Two months ago, BlissBio in-licensed exclusive rights to an antibody drug conjugate technology for a cancer target from Morphotek, a US subsidiary of Japan’s Eisai (TYO: 4523).
Source: China Biotoday
